Drug major Johnson & Johnson (JNJ) announced Friday that its TECVAYLI (teclistamab) monotherapy has been approved by the European Commission to treat adult patients with relapsed/refractory multiple myeloma or RRMM, expanding treatment options from first relapse.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.